Ads
related to: dfyne impact vs dynamic growth factor 7 deficiency treatment- Diagnosing PGHD
Testing and evaluation options
for Pediatric GHD.
- Managing PGHD
See the challenges of Pediatric
Growth Hormone Deficiency (PGHD).
- About PGHD
Learn the science behind Pediatric
Growth Hormone Deficiency (PGHD).
- Advocacy & Support
Download tools and resources for
your family's PGHD journey.
- Diagnosing PGHD
Search results
Results From The WOW.Com Content Network
Factor VII deficiency is a bleeding disorder characterized by a lack in the production of Factor VII (FVII) (proconvertin), a protein that causes blood to clot in the coagulation cascade. After a trauma factor VII initiates the process of coagulation in conjunction with tissue factor (TF/factor III) in the extrinsic pathway.
Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. [4] [5] It is administered via an injection into a vein.[6] [4] [5] It is used to treat bleeding episodes in people who have acquired haemophilia, among other indications. [7]
2155 14068 Ensembl ENSG00000057593 ENSMUSG00000031443 UniProt P08709 P70375 RefSeq (mRNA) NM_000131 NM_001267554 NM_019616 NM_010172 RefSeq (protein) NP_000122 NP_001254483 NP_062562 NP_034302 Location (UCSC) Chr 13: 113.11 – 113.12 Mb Chr 8: 13.08 – 13.09 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Coagulation factor VII (EC 3.4.21.21, formerly known as proconvertin) is a ...
Growth differentiation factor 7 (GDF7) is a protein that in humans is encoded by the GDF7 gene. [ 5 ] GDF7 belongs to the transforming growth factor beta superfamily that is specifically found in a signaling center known as the roof plate that is located in the developing nervous system of embryos .
This protein is a potent epithelial cell-specific growth factor, whose mitogenic activity is predominantly exhibited in keratinocytes but not in fibroblasts and endothelial cells. Studies of mouse and rat homologs of this gene implicated roles in morphogenesis of epithelium, reepithelialization of wounds, hair development and early lung ...
Prothrombin complex concentrate (PCC), also known as factor IX complex, sold under the brand name Kcentra among others, is a combination medication made up of blood clotting factors II, IX, and X [9] (3-factor PCC) or, when also containing factor VII as does Kcentra, 4-factor PCC. [10]
Many cases of congenital dysfibrinogenemia are asymptomatic. Since manifestations of the disorder generally occur in early adulthood or middle-age, younger individuals with a gene mutation causing it may not have had time to develop symptoms while previously asymptomatic individuals of advanced age with such a mutation are unlikely to develop symptoms.
Diagnosis involves blood tests to measure growth hormone levels. [2] Treatment is by growth hormone replacement using synthetic human growth hormone. [1] The frequency of the condition is unclear. [2] Most cases are initially noticed in children. [1] The genetic forms of this disease are estimated to affect about 1 in 7,000 people. [3]